MX2009009520A - Fenoxiaminotiazolonas sustituidas como moduladores del receptor alfa relacionados con estrogenos. - Google Patents
Fenoxiaminotiazolonas sustituidas como moduladores del receptor alfa relacionados con estrogenos.Info
- Publication number
- MX2009009520A MX2009009520A MX2009009520A MX2009009520A MX2009009520A MX 2009009520 A MX2009009520 A MX 2009009520A MX 2009009520 A MX2009009520 A MX 2009009520A MX 2009009520 A MX2009009520 A MX 2009009520A MX 2009009520 A MX2009009520 A MX 2009009520A
- Authority
- MX
- Mexico
- Prior art keywords
- arthritis
- disease
- cartilage
- chronic
- injury
- Prior art date
Links
- QOGFHXOSRWCQBZ-UHFFFAOYSA-N 1-oxo-4-phenoxy-1,3-thiazol-2-amine Chemical class O=S1C(N)=NC(OC=2C=CC=CC=2)=C1 QOGFHXOSRWCQBZ-UHFFFAOYSA-N 0.000 title 1
- 102100036832 Steroid hormone receptor ERR1 Human genes 0.000 title 1
- 108091008559 estrogen-related receptor alpha Proteins 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 206010003246 arthritis Diseases 0.000 abstract 2
- 210000000988 bone and bone Anatomy 0.000 abstract 2
- 210000000845 cartilage Anatomy 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000002574 reactive arthritis Diseases 0.000 abstract 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 abstract 1
- 206010003267 Arthritis reactive Diseases 0.000 abstract 1
- 208000025940 Back injury Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010006458 Bronchitis chronic Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010007710 Cartilage injury Diseases 0.000 abstract 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 abstract 1
- 208000005243 Chondrosarcoma Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000012514 Cumulative Trauma disease Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 208000004575 Infectious Arthritis Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000010191 Osteitis Deformans Diseases 0.000 abstract 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000027868 Paget disease Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 abstract 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 abstract 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 abstract 1
- 208000033464 Reiter syndrome Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 229940046836 anti-estrogen Drugs 0.000 abstract 1
- 230000001833 anti-estrogenic effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 230000022159 cartilage development Effects 0.000 abstract 1
- 208000002849 chondrocalcinosis Diseases 0.000 abstract 1
- 208000017568 chondrodysplasia Diseases 0.000 abstract 1
- 208000007451 chronic bronchitis Diseases 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000019439 energy homeostasis Effects 0.000 abstract 1
- 239000000328 estrogen antagonist Substances 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 208000027202 mammary Paget disease Diseases 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000011164 ossification Effects 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 230000000010 osteolytic effect Effects 0.000 abstract 1
- 208000005368 osteomalacia Diseases 0.000 abstract 1
- 208000028169 periodontal disease Diseases 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 201000001223 septic arthritis Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89346407P | 2007-03-07 | 2007-03-07 | |
| PCT/US2008/056029 WO2008109737A1 (en) | 2007-03-07 | 2008-03-06 | Substituted phenoxy aminothiazolones as estrogen related receptor-alpha modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009009520A true MX2009009520A (es) | 2009-11-18 |
Family
ID=39530136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009009520A MX2009009520A (es) | 2007-03-07 | 2008-03-06 | Fenoxiaminotiazolonas sustituidas como moduladores del receptor alfa relacionados con estrogenos. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8580832B2 (enExample) |
| EP (1) | EP2134698A1 (enExample) |
| JP (1) | JP2010520308A (enExample) |
| KR (1) | KR20090128454A (enExample) |
| CN (1) | CN101679327A (enExample) |
| AR (1) | AR065657A1 (enExample) |
| AU (1) | AU2008222755B2 (enExample) |
| BR (1) | BRPI0808776A2 (enExample) |
| CA (1) | CA2680212A1 (enExample) |
| CL (1) | CL2008000667A1 (enExample) |
| EA (1) | EA016887B1 (enExample) |
| IL (1) | IL200759A0 (enExample) |
| MX (1) | MX2009009520A (enExample) |
| NZ (1) | NZ579417A (enExample) |
| TW (1) | TW200902506A (enExample) |
| UA (1) | UA98484C2 (enExample) |
| WO (1) | WO2008109737A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI417095B (zh) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途 |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TWI475995B (zh) | 2007-09-14 | 2015-03-11 | 詹森藥物公司 | １’，３’－二取代－４－苯基－３，４，５，６－四氫－２ｈ，１’ｈ－〔１，４’〕聯吡啶基－２’－酮化物 |
| PL2200985T3 (pl) | 2007-09-14 | 2011-12-30 | Ortho Mcneil Janssen Pharmaceuticals Inc | 1,3-Dipodstawione-4-(arylo-X-fenylo)-1H-pirydyn-2-ony |
| WO2009033703A1 (en) | 2007-09-14 | 2009-03-19 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones |
| RU2492170C9 (ru) | 2007-11-14 | 2013-12-27 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | Имидазо[1,2-а]пиридиновые производные и их применение в качестве положительных аллостерических модуляторов рецепторов mglur2 |
| MX2011002042A (es) | 2008-09-02 | 2011-06-20 | Ortho Mcneil Janssen Pharm | Derivados de 3-azabiciclo[3.1.o]hexilo como moduladores de los receptores del glutamato metabotropico. |
| MX2011003691A (es) | 2008-10-16 | 2011-09-06 | Ortho Mcneil Janssen Pharm | Derivados de indol y benzomorfolina como moduladores de los receptores de glutamato metabotropico. |
| RU2512283C2 (ru) | 2008-11-28 | 2014-04-10 | Янссен Фармасьютикалз, Инк. | Производные индола и бензоксазина в качестве модуляторов метаботропных глутаматных рецепторов |
| NZ596078A (en) | 2009-05-12 | 2013-06-28 | Janssen Pharmaceuticals Inc | 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| AR076859A1 (es) | 2009-05-12 | 2011-07-13 | Ortho Mcneil Janssen Pharm | Derivados de 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2 , composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos. |
| JPWO2011016501A1 (ja) * | 2009-08-04 | 2013-01-10 | 武田薬品工業株式会社 | 癌の予防ないし治療薬 |
| WO2011019556A1 (en) | 2009-08-11 | 2011-02-17 | Janssen Pharmaceutica Nv | CO-CRYSTALLIZATION OF ERR-A α WITH A LIGAND THAT FORMS A REVERSIBLE CONVALENT BOND |
| WO2011019558A1 (en) * | 2009-08-11 | 2011-02-17 | Janssen Pharmaceutica Nv | Methods to measure dissociation rates for ligands that form reversible covalent bonds |
| US8263781B2 (en) | 2009-12-18 | 2012-09-11 | Janssen Pharmaceutica Nv | Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators |
| RU2012139459A (ru) * | 2010-02-17 | 2014-03-27 | Янссен Фармацевтика Нв | Аминотиазолоны для использования в качестве модуляторов родственных эстрогену рецепторов альфа |
| CN103298810B (zh) | 2010-11-08 | 2016-03-16 | 杨森制药公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
| WO2012062751A1 (en) | 2010-11-08 | 2012-05-18 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| JP5852666B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
| US8772277B2 (en) | 2011-08-04 | 2014-07-08 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
| AU2013238126C1 (en) | 2012-03-26 | 2018-06-14 | Nippon Chemiphar Co., Ltd. | Prophylactic or therapeutic agent for giant cell tumors occurring in bone and soft tissue or for chondrosarcoma |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| JP6527822B2 (ja) | 2013-09-25 | 2019-06-05 | 日本ケミファ株式会社 | 骨・軟部に発生する巨細胞性腫瘍、軟骨肉腫または骨肉腫の予防、治療または転移の予防のための薬剤、動脈塞栓術用局所注入剤、および、人工骨 |
| CN109999025A (zh) | 2014-01-21 | 2019-07-12 | 詹森药业有限公司 | 包括代谢型谷氨酸能受体亚型2的正别构调节物或正位激动剂的组合及其用途 |
| IL279202B2 (en) | 2014-01-21 | 2023-09-01 | Janssen Pharmaceutica Nv | Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| BR112021019256A2 (pt) * | 2019-03-28 | 2021-12-14 | Escient Pharmaceuticals Inc | Moduladores de receptor x4 de proteína g relacionado a mas e produtos e métodos relacionados |
| KR20220029719A (ko) * | 2019-07-04 | 2022-03-08 | 리드 파마 홀딩 비.브이. | 에스트로겐-관련 수용체 알파 조절제 |
| CN112538038B (zh) * | 2019-09-20 | 2022-05-20 | 暨南大学 | 2-吲哚酮类ERRα反向激动剂及其药物组合物和应用 |
| KR20220066822A (ko) | 2020-11-16 | 2022-05-24 | 경북대학교 산학협력단 | 골 질환 예방 또는 치료용 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5037842A (en) | 1990-06-05 | 1991-08-06 | Pfizer Inc. | Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents |
| JP2001072592A (ja) * | 1999-07-01 | 2001-03-21 | Kyowa Hakko Kogyo Co Ltd | テロメラーゼ阻害剤 |
| AU2001257022B2 (en) * | 2000-04-13 | 2005-02-03 | Mayo Foundation For Medical Education And Research | Abeta 42 lowering agents |
| DE10131899A1 (de) | 2001-07-04 | 2003-02-27 | Boehringer Ingelheim Pharma | In vitro-Screening-Assay für gamma-Secretase |
| EP1398029A1 (en) | 2002-09-10 | 2004-03-17 | LION Bioscience AG | NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives |
| US20080313061A1 (en) | 2004-06-30 | 2008-12-18 | Paysetter Pte Ltd | System and Method for Facilitating Transfer of Physical Money and/or Credit |
| BRPI0513367A (pt) * | 2004-07-14 | 2008-05-06 | Janssen Pharmaceutica Nv | arilidenos para o tratamento de doenças mediadas pelo receptor alfa relacionado a estrogênio |
| JP4931824B2 (ja) * | 2004-10-22 | 2012-05-16 | エグゼリクシス， インコーポレイテッド | 薬学的組成物 |
-
2008
- 2008-03-06 EP EP08731528A patent/EP2134698A1/en not_active Ceased
- 2008-03-06 WO PCT/US2008/056029 patent/WO2008109737A1/en not_active Ceased
- 2008-03-06 CA CA002680212A patent/CA2680212A1/en not_active Abandoned
- 2008-03-06 UA UAA200910122A patent/UA98484C2/ru unknown
- 2008-03-06 AU AU2008222755A patent/AU2008222755B2/en not_active Expired - Fee Related
- 2008-03-06 US US12/043,311 patent/US8580832B2/en not_active Expired - Fee Related
- 2008-03-06 JP JP2009552887A patent/JP2010520308A/ja active Pending
- 2008-03-06 EA EA200970839A patent/EA016887B1/ru not_active IP Right Cessation
- 2008-03-06 CL CL2008000667A patent/CL2008000667A1/es unknown
- 2008-03-06 MX MX2009009520A patent/MX2009009520A/es unknown
- 2008-03-06 BR BRPI0808776-8A patent/BRPI0808776A2/pt not_active IP Right Cessation
- 2008-03-06 CN CN200880015410A patent/CN101679327A/zh active Pending
- 2008-03-06 KR KR1020097020836A patent/KR20090128454A/ko not_active Withdrawn
- 2008-03-06 NZ NZ579417A patent/NZ579417A/en not_active IP Right Cessation
- 2008-03-06 TW TW097107931A patent/TW200902506A/zh unknown
- 2008-03-07 AR ARP080100964A patent/AR065657A1/es not_active Application Discontinuation
-
2009
- 2009-09-06 IL IL200759A patent/IL200759A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA200970839A1 (ru) | 2010-04-30 |
| UA98484C2 (ru) | 2012-05-25 |
| KR20090128454A (ko) | 2009-12-15 |
| AU2008222755B2 (en) | 2013-05-02 |
| NZ579417A (en) | 2012-02-24 |
| WO2008109737A1 (en) | 2008-09-12 |
| BRPI0808776A2 (pt) | 2014-08-19 |
| US20080221179A1 (en) | 2008-09-11 |
| CA2680212A1 (en) | 2008-09-12 |
| CL2008000667A1 (es) | 2008-11-03 |
| JP2010520308A (ja) | 2010-06-10 |
| US8580832B2 (en) | 2013-11-12 |
| EA016887B1 (ru) | 2012-08-30 |
| CN101679327A (zh) | 2010-03-24 |
| EP2134698A1 (en) | 2009-12-23 |
| IL200759A0 (en) | 2010-05-17 |
| AU2008222755A1 (en) | 2008-09-12 |
| TW200902506A (en) | 2009-01-16 |
| AR065657A1 (es) | 2009-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA98484C2 (ru) | ЗАМЕЩЕННЫЕ ФЕНОКСИАМИНОТИАЗОЛОНЫ КАК МОДУЛЯТОРЫ α-РЕЦЕПТОРА ЭСТРОГЕНА | |
| MX2009009517A (es) | Fenoxi tiazolidindionas sustituidas como moduladores del receptor alfa relacionado con el estrogeno. | |
| MX2009009519A (es) | Fenoxitiazolidinodionas n-alquiladas sustituidas como moduladores de receptor- alfa relacionados con estrogeno. | |
| MX2012009529A (es) | Aminotiazolonas como moduladores de receptores alfa relacionados con el estrógeno. | |
| MX2012009528A (es) | Aminotiazolonas como moduladores de receptores alfa relacionados con el estrógeno. | |
| JP2010520308A5 (enExample) | ||
| JP2010520307A5 (enExample) | ||
| WO2005115383A3 (en) | Substituted triazoles as modulators of ppar and methods of their preparation | |
| JP2012506473A5 (enExample) | ||
| JP2009513806A5 (enExample) | ||
| WO2014025406A1 (en) | Dental materials and method of manufacture | |
| CA2715113A1 (en) | 11 beta-hydroxysteroid dehydrogenase inhibitors | |
| UA97975C2 (ru) | ЗАМЕЩЕННЫЕ ФЕНОКСИПРОИЗВОДНЫЕ N-АЛКИЛОВАННЫЕ ТИАЗОЛИДИНДИОНЫ КАК МОДУЛЯТОРЫ ЭСТРОГЕН-РОДСТВЕННЫХ РЕЦЕПТОРОВ α | |
| WO2010007363A3 (en) | Preparation of fluorine-labelled compounds | |
| MY160230A (en) | Thermoplastic stiffening materials | |
| JP2012233153A5 (enExample) | ||
| WO2007077844A1 (ja) | アルケニルを有するモノフッ素化テルフェニル化合物、液晶組成物および液晶表示素子 | |
| CN110016124A (zh) | 一种基于二苯砜的A-π-D-π-A型增感剂及其制备方法、应用 | |
| JP2022056984A (ja) | ラジカル重合性モノマーを溶媒とした医科歯科用低重合収縮性モノマーの合成・製造方法 | |
| CN111072539A (zh) | 一种简便的硫代甲磺酸甲酯的制备方法 | |
| CN102898455B (zh) | 一种对甲基苯基二乙氧基甲基硅烷及其制备方法 | |
| JP2016023176A (ja) | 化合物及びその製造方法 | |
| CN107011212A (zh) | 一种氰乙酸仲辛酯的制备方法 | |
| EP2029639B1 (en) | Photopolymerizable compositions featuring novel amine accelerator for improved color stability and reduced polymerization stress thereby | |
| Weyhe | Mansnavnið Lagi í Føroyum/The Male Forename Lagi in the Faroes |